ADMA Biologics Inc (ADMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has a cash flow conversion efficiency ratio of 0.075x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($35.64 Million) by net assets ($477.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ADMA Biologics Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of ADMA Biologics Inc for a breakdown of total debt and financial obligations.
ADMA Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADMA Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Hope Dairy Co Ltd
SHE:002946
|
0.113x |
|
Odfjell Drilling Ltd
OL:ODL
|
0.063x |
|
ANSELL (UNSP.ADRS)/4
F:PD1
|
N/A |
|
Ral Yatirim Holding AS
IS:RALYH
|
0.214x |
|
Ebos Group Ltd
AU:EBO
|
0.011x |
|
Trustmark Corporation
NASDAQ:TRMK
|
0.027x |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
0.145x |
|
Netweb Technologies India Limited
NSE:NETWEB
|
N/A |
Annual Cash Flow Conversion Efficiency for ADMA Biologics Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of ADMA Biologics Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ADMA Biologics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $477.32 Million | $50.40 Million | 0.106x | -68.95% |
| 2024-12-31 | $349.02 Million | $118.67 Million | 0.340x | +422.41% |
| 2023-12-31 | $135.21 Million | $8.80 Million | 0.065x | +116.62% |
| 2022-12-31 | $151.97 Million | $-59.51 Million | -0.392x | +50.81% |
| 2021-12-31 | $141.17 Million | $-112.37 Million | -0.796x | +31.14% |
| 2020-12-31 | $88.25 Million | $-102.00 Million | -1.156x | +60.27% |
| 2019-12-31 | $26.19 Million | $-76.19 Million | -2.909x | +8.25% |
| 2018-12-31 | $19.77 Million | $-62.68 Million | -3.170x | -243.07% |
| 2017-12-31 | $40.33 Million | $-37.27 Million | -0.924x | -122.55% |
| 2016-12-31 | $-4.46 Million | $-18.27 Million | 4.099x | +121.82% |
| 2015-12-31 | $820.97K | $-15.42 Million | -18.781x | -667.40% |
| 2014-12-31 | $6.01 Million | $-14.70 Million | -2.447x | -384.94% |
| 2013-12-31 | $21.57 Million | $-10.89 Million | -0.505x | +31.11% |
| 2012-12-31 | $9.42 Million | $-6.90 Million | -0.733x | +92.99% |
| 2011-12-31 | $2.77K | $-29.00K | -10.458x | -118.39% |
| 2010-12-31 | $-346.00 | $-19.68K | 56.867x | -- |
| 2009-12-31 | $0.00 | $-24.46 Million | x | -- |
| 2008-12-31 | $0.00 | $-19.00 Million | x | -- |
| 2007-12-31 | $0.00 | $-23.61 Million | x | -- |
| 2006-12-31 | $0.00 | $-23.61 Million | x | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more